Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Hutchison China Meditech (HCM) ORD USD0.10

Sell:410.50p Buy:414.00p 0 Change: 5.50p (1.31%)
FTSE AIM 100:0.18%
Market closed Prices as at close on 19 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:410.50p
Buy:414.00p
Change: 5.50p (1.31%)
Market closed Prices as at close on 19 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:410.50p
Buy:414.00p
Change: 5.50p (1.31%)
Market closed Prices as at close on 19 April 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.

Contact details

Address:
22Nd Floor Hutchison House
10 Harcourt Road

00000
Hong Kong
Telephone:
+852 (0) 21213888
Website:
https://www.chi-med.com/

Important dates

Future events
AGM 28 April 2021 28/04/21
Past events
Annual report 26 March 2021 26/03/21
Final results 04 March 2021 04/03/21
Interim results 30 July 2020 30/07/20
AGM 27 April 2020 27/04/20

General stock information

EPIC:
HCM
ISIN:
KYG4672N1198
Market cap:
£3.08 billion
Shares in issue:
744.52 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
FTSE AIM 100,FTSE AIM All Share

Key personnel

  • Simon To
    Executive Chairman of the Board
  • Christian Hogg
    Chief Executive Officer, Executive Director
  • Chig Fung Cheng
    Chief Financial Officer, Executive Director
  • Mark Lee
    Senior Vice President - Corporate Finance & Development
  • May Wang
    Senior Vice President - business development & strategic alliances
  • Zhenping Wu
    Senior Vice President - Pharmaceutical Sciences
  • Weiguo Su
    Chief Scientific Officer, Executive Director
  • Edith Shih
    Company Secretary, Non-Executive Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.